Nuria Montero

Nuria Montero

Auto-generated profile, based on publicly available information

Nuria Montero

Nephrology Department, Hospital Universitari de Bellvitge

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2020 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
LHLuuk B Hilbrands
Luuk B Hilbrands
RDRaphaël Duivenvoorden
Raphaël Duivenvoorden
PVPriya Vart
Priya Vart
CFCasper F M Franssen
Casper F M Franssen
MHMarc H Hemmelder
Marc H Hemmelder
NBNicole Heitink-Ter Braak
Nicole Heitink-Ter Braak
Background. Patients on kidney replacement therapy comprise a vulnerable population and may be at increased risk of death from coronavirus disease 2019 (COVID-19). Currently, only limited data are available on outcomes in this patient population. Methods. We set up the ERACODA (European Renal Association COVID-19 Database) database, which is specifically designed to prospectively collect detailed data on kidney transplant and dialysis patients with COVID-19. For this analysis, patients were included who presented between 1 February and 1 May 2020 and had complete information available on the primary outcome parameter, 28-day mortality. Results. Of the 1073 patients enrolled, 305 (28%) were kidney transplant and 768 (72%) dialysis patients with a mean age of 60 ± 13 and 67 ± 14 years, respectively. The 28-day probability of death was 21.3% [95% confidence interval (95% CI) 14.3–30.2%] in kidney transplant and 25.0% (95% CI 20.2–30.0%) in dialysis patients. Mortality was primarily associated with advanced age in kidney transplant patients, and with age and frailty in dialysis patients. After adjusting for sex, age and frailty, in-hospital mortality did not significantly differ between transplant and dialysis patients [hazard ratio (HR) 0.81, 95% CI 0.59–1.10, P = 0.18]. In the subset of dialysis patients who were a candidate for transplantation (n = 148), 8 patients died within 28 days, as compared with 7 deaths in 23 patients who underwent a kidney transplantation <1 year before presentation (HR adjusted for sex, age and frailty 0.20, 95% CI 0.07–0.56, P < 0.01). Conclusions. The 28-day case-fatality rate is high in patients on kidney replacement therapy with COVID-19 and is primarily driven by the risk factors age and frailty. Furthermore, in the first year after kidney transplantation, patients may be at increased risk of COVID-19-related mortality as compared with dialysis patients on the waiting list for transplantation. This information is important in guiding clinical decision-making, and for informing the public and healthcare authorities on the COVID-19-related mortality risk in kidney transplant and dialysis patients.

3 January 2024 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
ASAdnan Sharif
Adnan Sharif
HCHarini Chakkera
Harini Chakkera
AVAiko P.J. de Vries
Aiko P.J. de Vries
KEKathrin Eller
Kathrin Eller
MGMartina Guthoff
Martina Guthoff
Manfred HeckingManfred Hecking
Manfred Hecking
Post-transplantation diabetes mellitus (PTDM) remains a leading complication after solid organ transplantation. Previous international PTDM consensus meetings in 2003 and 2013 provided standardized frameworks to reduce heterogeneity in diagnosis, risk stratification and management. However, the last decade has seen significant advancements in our PTDM knowledge complemented by rapidly changing treatment algorithms for management of diabetes in the general population. In view of these developments, and to ensure reduced variation in clinical practice, a 3rd international PTDM Consensus Meeting was planned and held from 6–8 May 2022 in Vienna, Austria involving global delegates with PTDM expertise to update the previous reports. This update includes opinion statements concerning optimal diagnostic tools, recognition of prediabetes (impaired fasting glucose and/or impaired glucose tolerance), new mechanistic insights, immunosuppression modification, evidence-based strategies to prevent PTDM, treatment hierarchy for incorporating novel glucose-lowering agents and suggestions for the future direction of PTDM research to address unmet needs. Due to the paucity of good quality evidence, consensus meeting participants agreed that making GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) recommendations would be flawed. Although kidney-allograft centric, we suggest that these opinion statements can be appraised by the transplantation community for implementation across different solid organ transplant cohorts. Acknowledging the paucity of published literature, this report reflects consensus expert opinion. Attaining evidence is desirable to ensure establishment of optimized care for any solid organ transplant recipient at risk of, or who develops, PTDM as we strive to improve long-term outcomes.

7 August 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SLSergi Luque
Sergi Luque
MLMarc Lúcia
Marc Lúcia
EMEdoardo Melilli
Edoardo Melilli
CLCarmen Lefaucheur
Carmen Lefaucheur
MCMarta Crespo
Marta Crespo
OBOriol Bestard
Oriol Bestard
Antibody‐mediated rejection (ABMR) is defined by specific histopathological lesions and evidence of circulating donor‐specific antibodies (DSA). While DSA are not always detectable, monitoring donor‐reactive memory B‐cells (mBC) could recognize at‐risk patients of developing ABMR. Peripheral donor‐reactive mBC using a novel HLA B‐cell ELISpot assay, serum DSA and numbers of different B‐cell subsets were assessed in 175 consecutive kidney transplants undergoing either for‐cause or 6 and 24‐month surveillance biopsies for their association with main histological lesions of ABMR and impact on allograft outcome. In 85 incident for‐cause biopsies, high frequencies of donor‐reactive mBC were detected in all 16(100%) acute ABMR/DSA+ and most chronic ABMR, with or without DSA (24/30[80%] and 21/29[72.4%], respectively). In a longitudinal cohort of 90 non‐sensitized patients, a progressively higher expansion of donor‐reactive mBC than de novo DSA was observed at 6 and 24 months (8.8% vs 7.7% and 15.5% vs 11.1%, respectively) and accurately identified patients with on‐going subclinical ABMR (AUC=0.917 and AUC=0.809, respectively). An unsupervised hierarchical cluster analysis revealed a strong association between donor‐reactive mBC with main fundamental allograft lesions associated to ABMR and conferred a significant deleterious impact on graft outcome.

10 August 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
AFAlexandre Favà
Alexandre Favà
DCDavid Cucchiari
David Cucchiari
NMNuria Montero
Nuria Montero
NTNestor Toapanta
Nestor Toapanta
FCFrancisco J. Centellas
Francisco J. Centellas
EMEdoardo Melilli
Edoardo Melilli
Kidney transplant recipients might be at higher risk for severe coronavirus disease 2019 (COVID‐19). However, risk factors for relevant outcomes remain uncertain in this population. This is a multicentric kidney transplant cohort including 104 hospitalized patients between Mar 4 and Apr 17, 2020. Risk factors for death and acute respiratory distress syndrome (ARDS) were investigated, and clinical and laboratory data was analyzed. The mean age was 60 years. Forty‐seven patients (54.8%) developed ARDS. Obesity was associated to ARDS development (OR 2.63; p=0.04). Significant age differences were not found among patients developing and not developing ARDS (61.3yr vs 57.8yr, p=0.16). Seventy‐six (73%) patients were discharged while 28 (27%) died. Death was more common among the elderly (55yr and 70.8yr, p<0.001) and those with preexisting pulmonary disease (OR 2.89 , p=0.009). At admission, higher baseline lactate dehydrogenase (257 IU/ml vs 358 IU/ml, p=0.001) or ARDS conferred higher risk of death (HR 2.09, p=0.044). In our cohort, ARDS was equally present among young and old kidney recipients. However, the elderly might be at higher risk of death, along with those showing higher baseline LDH at admission.

1 April 2017 in Transplantation
Verified
Journal Article
Closed access
MPMaría José Pérez-Sáez
María José Pérez-Sáez
NMNúria Montero
Núria Montero
DRDolores Redondo-Pachón
Dolores Redondo-Pachón
MCMarta Crespo
Marta Crespo
JPJulio Pascual
Julio Pascual
The old-for-old allocation policy used for kidney transplantation (KT) has confirmed the survival benefit compared to remaining listed on dialysis. Shortage of standard donors has stimulated the development of strategies aimed to expand acceptance criteria, particularly of kidneys from elderly donors. We have systematically reviewed the literature on those different strategies. In addition to the review of outcomes of expanded criteria donor or advanced age kidneys, we assessed the value of the Kidney Donor Profile Index policy, preimplantation biopsy, dual KT, machine perfusion and special immunosuppressive protocols. Survival and functional outcomes achieved with expanded criteria donor, high Kidney Donor Profile Index or advanced age kidneys are poorer than those with standard ones. Outcomes using advanced age brain-dead or cardiac-dead donor kidneys are similar. Preimplantation biopsies and related scores have been useful to predict function, but their applicability to transplant or refuse a kidney graft has probably been overestimated. Machine perfusion techniques have decreased delayed graft function and could improve graft survival. Investing 2 kidneys in 1 recipient does not make sense when a single KT would be enough, particularly in elderly recipients. Tailored immunosuppression when transplanting an old kidney may be useful, but no formal trials are available. Old donors constitute an enormous source of useful kidneys, but their retrieval in many countries is infrequent. The assumption of limited but precious functional expectancy for an old kidney and substantial reduction of discard rates should be generalized to mitigate these limitations.

23 March 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
AFAlexandre Favà
Alexandre Favà
LDLaura Donadeu
Laura Donadeu
NSNuria Sabé
Nuria Sabé
VPVincent Pernin
Vincent Pernin
JGJosé González-Costello
José González-Costello
OBOriol Bestard
Oriol Bestard
The description of protective humoral and T‐cell immune responses specific against SARS‐CoV‐2 has been reported among immunocompetent (IC) individuals developing COVID‐19 infection. However, its characterization and determinants of poorer outcomes among the at‐risk Solid Organ Transplant (SOT) patient population has not been thoroughly investigated. Cytokine‐producing T‐cell responses such as IFN‐γ, IL‐2, IFN‐γ/IL‐2, IL‐6, IL‐21 and IL‐5 against main immunogenic SARS‐CoV‐2 antigens and IgM/IgG serological immunity were tracked in SOT (n=28) during acute infection and at 2 consecutive time‐points over the following 40 days of convalescence and were compared to matched IC (n=16) patients admitted with similar moderate/severe COVID‐19. We describe the development of a robust serological and functional T‐cell immune responses against SARS‐CoV‐2 among SOT patients, similarly to IC patients during early convalescence. However, at the infection onset, SOT displayed lower IgG seroconversion rates (77% vs 100%; p=0.044), despite no differences on IgG titters, and a trend towards decreased SARS‐CoV‐2‐reactive T‐cell frequencies, especially against the membrane protein (7[0‐34] vs 113[15‐45] p=0.011, 2[0‐9] vs 45[5‐74], p=0.009 and 0[0‐2] vs 13[1‐24], p=0.020, IFN‐γ, IL‐2 and IFN‐γ/IL‐2 spots, respectively). In summary, our data suggest that despite a certain initial delay, SOT achieve comparable functional immune responses than the general population after moderate/severe COVID‐19.